Vivaxin malaria vaccine safety and immune response trial
Part of Infections clinical trials.
This trial tests the safety and immune response of an experimental vaccine called Vivaxin, designed to protect against malaria caused by the Plasmodium vivax parasite. Healthy adults aged 18–59 who have never had malaria may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 59 years old.
- You are in good general health (no serious or chronic medical conditions).
- You have never had malaria or received a malaria vaccine.
- If you could become pregnant, you agree to use an effective birth control method for at least 30 days before the first shot and for 6 months after.
- You agree not to donate blood during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medicines (tafenoquine and primaquine) taken with chloroquine to treat P. vivax malaria. It aims to see which is safer and works better in Indian participants aged 2 to 64.
This study tests how well a malaria treatment plan works for people with P. vivax malaria who don’t have another malaria type at the same time. It aims to see whether adding or using different medicines (ACT vs chloroquine with tafenoquine) helps clear infection and prevent return of disease.
This trial tests a new malaria vaccine in healthy adults. It aims to see if the vaccine is safe and can protect against malaria, including using a controlled infection to test effectiveness.
This study gives healthy adults who have never had malaria a controlled infection with the parasite that causes malaria, to see if it is safe and if mosquitoes can pick up the parasite from them. It may help develop new ways to prevent malaria.
This Phase 2 trial tests a malaria vaccine (PvRII/Matrix-M) and how well it trains the immune system, then follows safety and effectiveness after a controlled malaria exposure. If you qualify, you’ll be monitored closely in the hospital and receive a curative antimalarial treatment after the exposure.
This study tests an experimental malaria vaccine (CVD 36000) in healthy volunteers aged 18–50. Researchers will give you the vaccine and later expose you to malaria parasites in a controlled setting to see if the vaccine protects you. This helps develop a safer vaccine for people in malaria-prone countries.
Hear when a new Malaria Vivax trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.